Gossamer Bio Inc.

0.90
0.07 (8.77%)
At close: Apr 23, 2025, 3:59 PM
0.91
1.05%
Pre-market: Apr 24, 2025, 04:01 AM EDT
8.77%
Bid 0.87
Market Cap 203.11M
Revenue (ttm) 114.7M
Net Income (ttm) -56.53M
EPS (ttm) -0.25
PE Ratio (ttm) -3.59
Forward PE -1.88
Analyst Buy
Ask 1.03
Volume 2,296,308
Avg. Volume (20D) 1,572,818
Open 0.86
Previous Close 0.83
Day's Range 0.86 - 0.96
52-Week Range 0.50 - 1.55
Beta 1.88

About GOSS

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colonystimulating factor 1 receptor, or CSF1R, and c-KIT inhibitor for the treatment of pulmonary arterial hy...

Industry Biotechnology
Sector Healthcare
IPO Date Feb 8, 2019
Employees 144
Stock Exchange NASDAQ
Ticker Symbol GOSS
Full Company Profile

Analyst Forecast

According to 4 analyst ratings, the average rating for GOSS stock is "Buy." The 12-month stock price forecast is $8, which is an increase of 792.56% from the latest price.

Stock Forecasts

Next Earnings Release

Gossamer Bio Inc. is scheduled to release its earnings on May 6, 2025, during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription
10 months ago
Gossamer Bio shares are trading higher after Oppen... Unlock content with Pro Subscription
10 months ago
Gossamer Bio shares are trading higher after competitor Aerovate Therapeutics reported topline results from the Phase 2b portion of IMPAHCT trial of AV-101 for pulmonary arterial hypertension.